Remibrutinib lowers systemic disease activity in Sjögren’s syndrome
A selective oral BTK inhibitor moved into Sjögren’s syndrome with a clear signal on physician-assessed disease activity. In the 24-week phase 2 LOUiSSE trial, remibrutinib produced a significantly greater reduction in ESSDAI than placebo, with a treatment difference of −2.86 points and a p value of 0.003. For a disease defined by immune-mediated glandular and extra-glandular injury, the result matters because BTK sits upstream of B-cell receptor signaling and innate immune activation, two pathways central to Sjögren’s biology. Blocking that node can plausibly dampen the inflammatory machinery that drives systemic manifestations, even when symptoms are harder to move in the same time frame.
The study enrolled patients with moderate-to-severe disease who met 2016 ACR/EULAR classification criteria and were anti-Ro positive, with baseline activity high enough to require both a weighted ESSDAI score of at least 5 and an ESSPRI of at least 5. Participants received remibrutinib 100 mg once or twice daily, or placebo, over 24 weeks in a randomized, double-blind, placebo-controlled design. The trial therefore tested a biologically rational hypothesis in a relatively enriched population rather than a mixed cohort with low inflammatory burden.
One sentence captures the main clinical split: systemic inflammation moved, patient-reported symptoms did not.
Symptom scores lagged behind the inflammatory readout
The absence of benefit in ESSPRI is not a minor footnote. ESSPRI tracks dryness, pain, and fatigue, symptoms that often persist after immune activity is partially suppressed and that may reflect structural gland damage, neural sensitization, and non-inflammatory symptom amplification. In this trial, the change in ESSPRI at 24 weeks was 0.17 versus placebo, with a p value of 0.663, leaving no evidence of a meaningful symptomatic advantage over the study period.
That divergence between ESSDAI and ESSPRI is clinically important because it separates inflammatory control from lived experience. A therapy can reduce objective disease activity without immediately restoring salivary function, reversing fatigue, or altering chronic pain. In Sjögren’s syndrome, where glandular injury may be established before treatment begins, symptom relief may require longer exposure, different mechanisms, or combination strategies that address both inflammation and tissue dysfunction.
The study also followed ESSDAI and ESSPRI over time, which is the right framework for a disorder with fluctuating systemic features. A 24-week window is long enough to detect early pharmacodynamic effects on immune activity, but it may still be short for patient-facing outcomes that depend on glandular repair or reversal of entrenched extraglandular damage. The result is a familiar but still sobering pattern in autoimmune therapeutics: the biology moves first, symptoms may lag behind.
Salivary flow and biomarker shifts point to target engagement
A trend toward improvement in unstimulated salivary flow emerged with remibrutinib relative to placebo over 24 weeks. The study does not present a definitive symptomatic or functional breakthrough on this measure, but the direction of effect is consistent with a drug acting on immune processes relevant to glandular function. In Sjögren’s syndrome, salivary impairment reflects both inflammatory infiltration and progressive acinar dysfunction, so any improvement in flow can be interpreted cautiously as a signal of possible glandular benefit rather than proof of tissue recovery.
The exploratory biomarker work strengthens that interpretation. Remibrutinib induced significant changes in gene expression in blood and altered serum protein abundance compared with placebo. Those molecular shifts matter because they show biological engagement beyond clinical scoring alone. A BTK inhibitor should not only reduce visible disease activity; it should also modify circulating immune signatures that reflect B-cell and related inflammatory pathways. In a phase 2 trial, such translational data help connect the bedside signal to mechanism and make the clinical readout more credible.
The mechanistic logic is straightforward. BTK inhibition can disrupt signaling in B cells and other immune cells involved in autoantibody-associated inflammation, making it plausible that systemic disease activity would fall before symptom scores fully respond. Sjögren’s syndrome has always been a difficult target for this kind of separation, because the disease straddles measurable immune activity and patient-experienced dryness, pain, and fatigue. A treatment that changes one domain but not the other still provides useful information about where the disease is biologically tractable.
Safety remained favorable over 24 weeks
Safety was a central question in a chronic autoimmune condition that may require prolonged treatment. Over 24 weeks, remibrutinib had a favorable safety profile in patients with Sjögren’s syndrome. No new safety concern emerged from the abstract-level data provided here, and the study’s overall tolerability supports further evaluation of the drug in this population.
That matters because oral BTK inhibition is only as useful as its risk-benefit balance in a disease that is long lasting and often treated symptomatically for years. Patients with Sjögren’s syndrome may not accept meaningful immunomodulation unless the safety profile is stable enough for chronic use. A favorable short-term safety signal therefore does not settle the question, but it does keep the program clinically viable.
For prescribers, the immediate implication is not that remibrutinib should be adopted now, but that a targeted oral agent can reduce systemic inflammatory activity in a disorder where many prior strategies have struggled to show consistent benefit. The trial supports the idea that B-cell signaling remains a valid therapeutic axis in Sjögren’s syndrome, even if symptom improvement may require a longer horizon or a broader treatment strategy.
Why the result matters for future Sjögren’s trials
Phase 2 studies in Sjögren’s syndrome often fail because they chase endpoints that do not move in parallel. This trial avoids that trap by separating systemic disease activity from patient-reported symptoms and by including exploratory molecular readouts that can help explain discordant clinical outcomes. The design also focused on anti-Ro-positive patients with active disease, which likely enriched the sample for immunologically driven inflammation.
The data now point to a specific development path. Future studies will need to determine whether the ESSDAI benefit persists, whether larger and longer trials can capture a meaningful change in ESSPRI, and whether salivary function can be improved in a way that patients can feel. Biomarker changes may help identify who responds and which immune pathways are most dependent on BTK signaling. The unanswered clinical problem is not whether remibrutinib touches the disease biology; it clearly does. The harder question is whether that biology can be translated into durable symptom relief and organ-level recovery in a chronic autoimmune disorder with substantial established damage.